View Author
prostate cancer prostate cancer screening antigen study biopsy baseline speci level urology model result baseline psa levels prostate-speci fic antigen detection testing trial prostate-speci population speci ficity volume mortality european rectal examination randomized gleason psa testing diagnosis analysis free-to-total psa prostate cancer detection prostate cancer screening baseline psa measurements free-to-total erspc measurement baseline psa testing prostate cancer risk score ficity p 2psa psa levels catalona department patient european randomized study prostate cancer diagnosis value baseline psa relationship participant cohort dre-based prostate health index 10 ng /ml hg pca psa screening university serum group american calculator validation cohort prostatectomy examination mortality results validation dre-based rc rectal disease baseline psa level sensitivity rotterdam pca detection evidence range prostate biopsy prediction schroder
5 Most Recent Publications
|
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
(Article)
Loeb, S. Sokoll, L. Marks, L.S. Mizrahi, I.A. Shin, S.S. Cruz, A.B. Chan, D.W. Roberts, W.L. Catalona, W.J. Broyles, D.L. Bangma, C.H. Schaik, R.H.N. van Klee, G.G. Wei, J.T. Sanda, M.G. Partin, A.W. Slawin, K.M. |
2013-03-22
|
|
Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators
(Article)
Roobol, M.J. Vugt, H.A. van Loeb, S. Zhu, X.D. Bul, M. Bangma, C.H. Leenders, A.G.L.J.H. van Steyerberg, E.W. Schröder, F.H. |
2012-03-01
|
|
Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen-Based Risk Assessment in Younger Men. Eur Urol 2012;61:8-9
(Article)
Loeb, S. Carter, H.B. Catalona, W.J. Moul, J. Schröder, F.H. |
2012-01-01
|
|
Baseline prostate-specific antigen testing at a young age
(Article)
Loeb, S. Carter, H.B. Catalona, W.J. Moul, J. Schröder, F.H. |
2012-01-01
|
|
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
(Article)
Catalona, W.J. Partin, A.W. Shin, S.S. Cruz, A.B. Chan, D.W. Sokoll, L.J. Roberts, W.L. Schaik, R.H.N. van Mizrahi, I.A. Sanda, M.G. Wei, J.T. Klee, G.G. Bangma, C.H. Slawin, K.M. Marks, L.S. Loeb, S. Broyles, D.L. |
2011-05-01
|